title: Hypofractionation with simultaneous integrated boost for early breast cancer: results of the German multicenter phase II trial (ARO-2010-01).
abstract: OBJECTIVE
  To evaluate the feasibility of hypofractionation with SIB in all settings in Germany to prepare a multicenter treatment comparison.
  
  
  METHODS
  Eligible patients had histopathologically confirmed breast cancer operated by BCS. Patients received WBI 40.0 Gy in 16 fractions of 2.5 Gy. A SIB with 0.5 Gy per fraction was administered to the tumor bed, thereby giving 48.0 Gy in 16 fractions to the boost-PTV sparing heart, LAD, lung, contralateral breast. The primary study objective was feasibility, administration of specified dose in 16 fractions within 22-29 days with adherence to certain dose constraints (heart; LAD; contralateral breast); secondary endpoints were toxicity, QoL.
  
  
  RESULTS
  151 patients were recruited from 7 institutions between 07/11-10/12. 10 patients met exclusion criteria prior to irradiation. All but two patients (99%) received the prescribed dose in the PTVs. Adherence to dose constraints and time limits was achieved in 89% (95% CI 82% to 93%). 11 AE were reported in 10 patients; five related to concurrent endocrine therapy. Two of the AEs were related to radiotherapy: grade 3 hot flushes in two cases. QoL remained unchanged.
  
  
  CONCLUSIONS
  Hypofractionation with a SIB is feasible and was well tolerated in this study.
authors.affiliation: Department of Radiooncology, University of Kiel, A.-Heller-Str. 3, 24105, Kiel, Germany, Kathrin.Dellas@uksh.de.
authors.forename: Kathrin
authors.initials: K
authors.lastname: Dellas
authors.forename: Reinhard
authors.initials: R
authors.lastname: Vonthein
authors.forename: Jörg
authors.initials: J
authors.lastname: Zimmer
authors.forename: Stefan
authors.initials: S
authors.lastname: Dinges
authors.forename: Alexander D
authors.initials: AD
authors.lastname: Boicev
authors.forename: Peter
authors.initials: P
authors.lastname: Andreas
authors.forename: Dorothea
authors.initials: D
authors.lastname: Fischer
authors.forename: Cornelia
authors.initials: C
authors.lastname: Winkler
authors.forename: Andreas
authors.initials: A
authors.lastname: Ziegler
authors.forename: Jürgen
authors.initials: J
authors.lastname: Dunst
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000532:radiotherapy*; D019583:Dose Fractionation, Radiation; D042241:Early Diagnosis; D005240:Feasibility Studies; D005260:Female; D005858:Germany; D006801:Humans; D008875:Middle Aged; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000379:methods*; D016896:Treatment Outcome
references.citation: Strahlenther Onkol. 2013 Mar;189(3):193-6
references.pmid: 23358687
references.citation: Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1029-34
references.pmid: 19395193
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3259-65
references.pmid: 17577015
references.citation: Lancet Oncol. 2006 Jun;7(6):467-71
references.pmid: 16750496
references.citation: Cancer Radiother. 2008 Nov;12(6-7):571-6
references.pmid: 18703372
references.citation: Clin Breast Cancer. 2012 Feb;12(1):57-62
references.pmid: 22056970
references.citation: Lancet. 2008 Mar 29;371(9618):1098-107
references.pmid: 18355913
references.citation: Lancet. 2005 Dec 17;366(9503):2087-106
references.pmid: 16360786
references.citation: Radiat Oncol. 2012 Jun 01;7:80
references.pmid: 22656865
references.citation: N Engl J Med. 2013 Mar 14;368(11):987-98
references.pmid: 23484825
references.citation: Lancet. 2011 Nov 12;378(9804):1707-16
references.pmid: 22019144
references.citation: Strahlenther Onkol. 2013 Oct;189(10):825-33
references.pmid: 24002382
references.citation: Lancet Oncol. 2008 Apr;9(4):331-41
references.pmid: 18356109
references.citation: N Engl J Med. 2010 Feb 11;362(6):513-20
references.pmid: 20147717
references.citation: J Clin Oncol. 2000 Mar;18(6):1220-9
references.pmid: 10715291
references.citation: Radiat Oncol. 2012 Aug 28;7:145
references.pmid: 22929062